drugset / Trial / NCT01238770
Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The current trial shall clarify the potential of the multitarget antiangiogenic tyrosinkinase inhibitor GW 786034 (pazopanib) in combination with oral cyclophosphamide as salvage treatment in patients with recurrent, pretreated ovarian cancer.
Timeline
- Start
- 2010-11
- Primary completion
- 2014-10
- Completion
- 2015-10
Publications
- Dinkic C, Eichbaum M, Schmidt M, Grischke EM, Gebauer G, Fricke HC, Lenz F, Wallwiener M, Marme F, Schneeweiss A, Sohn C, Rom J. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Gynecol Oncol. 2017 Aug;146(2):279-284. doi: 10.1016/j.ygyno.2017.05.013. Epub 2017 May 19.
- Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T, Lenz F, Fricke HC, Solomayer E, Fersis N, Schmidt M, Wallwiener M, Schneeweiss A, Sohn C. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer. 2011 Oct 20;11:453. doi: 10.1186/1471-2407-11-453.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 400 mg | Oral |
| Subject | Pazopanib | Small molecule | 600 mg | Oral |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 50 mg | Oral |